EA Microarray Proficiency Testing Program Progresses, But Will the FDA Require It? | GenomeWeb

Expression Analysis is preparing to begin a second round of its proficiency testing program for microarray facilities, in which it compares variability in Affymetrix gene expression experiment outcomes among different labs and within labs.

But while experts agree that standardization will be important to the industry, whether or not the US Food and Drug Administration will require proficiency testing as a basis for approval remains a big question.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.